<DOC>
	<DOCNO>NCT01909778</DOCNO>
	<brief_summary>This trial intend investigate pharmacokinetics , safety tolerability BI 201335 NA soft-gel capsule patient compensate liver cirrhosis , i.e . grade A accord Child-Pugh classification ( &lt; 7 point ) .</brief_summary>
	<brief_title>Open Label Single Dose Phase I Trial BI 201335 Study Pharmacokinetics Safety Patients With Compensated Liver Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients liver cirrhosis , histologically proven previous liver biopsy ; possible aetiology : cure HCV infection , former alcohol abuse , genetic haemochromatosis , nonalcoholic steatohepatitis others . 2 . Compensated liver disease , indicate Prothrombin time INR prolong &lt; 1.7 x ULN , serum bilirubin &lt; 2 mg/dl , albumin &gt; 3.5 g/dl , ascites encephalopathy ( ChildPugh grade A , score &lt; 7 ) 3 . Age 18 year old 4 . Male patient , female document hysterectomy , ovariectomy tubal ligation OR menopausal female last menstrual period least 12 month prior screen OR female childbearing potential negative serum pregnancy test screen day 1 willing ensure consistent correct contraception 5 . Written inform consent prior study enrolment must consistent international conference harmonisation Â¿ good clinical practice ( ICHGCP ) local legislation . Exclusion criterion : 1 . Serological evidence active HBV , HCV HIV infection ( i.e . seropositivity HBs antigen , antiHIV1 2 antibody ; antiHCV antibody positive , patient must document negative HCV RNA least 12 month ) 2 . Usage drug within 7 day 5 halftime , whichever longer , prior treatment ; plan usage drug course current study 3 . Usage investigational drug within 30 day prior treatment ; plan usage investigational drug course current study 4 . Decompensated liver disease within past 12 month , indicate variceal bleeding , ascites , encephalopathy , Prothrombin time INR prolong &gt; 1,7 x ULN , serum bilirubin &gt; 2 mg/dl albumin &lt; 3,5 g/dl ( i.e . ChildPugh grade B ) 5 . ALT AST level &gt; 5xULN , Alkaline Phosphatase &gt; 2xULN 6 . Liver cirrhosis due primary secondary biliary cirrhosis , sclerosing cholangitis , vanish bile duct disease 7 . History alcohol abuse within past 3 month 8 . Known hypersensitivity content study drug 9 . Pregnant breast feeding females 10 . Females childbearing potential willing ensure consistent correct use condom least one additional medically accept method contraception ( diaphragm spermicidal substance , cervical cap ) unwilling comply complete abstinence , date screen 6 month last dose study drug 11 . AFP value &gt; 100 ng/ml ; AFP &gt; 20 &lt; = 100 ng/ml , patient include liver cancer exclude two congruent image study ( i.e . ultrasound plus CT scan MRI ) 12 . Evidence chronic kidney failure ( i.e . serum creatinine &gt; ULN ) 13 . Haemoglobinopathy ( e.g. , thalassaemia major sickle cell anaemia ) 14 . Concomitant intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness social situation would limit compliance trial requirement consider relevant evaluation pharmacokinetic parameter safety trial drug . 15 . Active suspect malignancy history malignancy within last 2 year ( exception appropriately treat basal cell carcinoma situ carcinoma uterine cervix )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>